Clinical Trial

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administration of the MMRV (Merck's measles, mumps, rubella and varicella) vaccine (ProQuad) that is already licensed for this route, when administered as a second dose in children 15 months to 6 years of age who were previously primed with a first dose of any combination of measles, mumps, rubella and varicella-containing vaccine(s).
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-09
notable Trial sites expanded: 0 -> 17 locations 2026-07-09
Trial Details
NCT Number NCT07406360
Lead Sponsor GlaxoSmithKline
Conditions Measles, Measles-Mumps-Rubella+Chickenpox Vaccine
Enrollment 1,209 participants
Start Date 2026-05-11
Primary Completion 2028-02-28 (estimated)
Study Completion 2028-07-20 (estimated)
Updated on ClinicalTrials.gov 2026-07-08